---
title: "Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286457097.md"
description: "Analyst Jason McCarthy of Maxim Group has reiterated a Buy rating on Moleculin Biotech, maintaining a price target of $10. The decision is based on positive developments in the MIRACLE trial for annamycin in treating relapsed/refractory AML, showing higher remission rates compared to historical data. McCarthy believes these results reduce development risks and could serve as a significant value catalyst for MBRX, supporting future growth and justifying the price target."
datetime: "2026-05-14T19:25:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286457097.md)
  - [en](https://longbridge.com/en/news/286457097.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286457097.md)
---

# Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Moleculin Biotech, retaining the price target of $10.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Jason McCarthy has given his Buy rating due to a combination of factors tied mainly to the advancing MIRACLE trial for annamycin in second-line relapsed/refractory AML and the strength of the early efficacy signals. Blinded interim results in the first 45 patients show composite and complete remission rates meaningfully higher than historical outcomes for high-dose cytarabine alone after multiple treatment cycles, hinting at a substantial treatment effect from annamycin.

McCarthy believes that these data not only align with prior clinical experience showing annamycin’s ability to induce rapid remissions without cardiotoxicity, but also partially reduce the development risk ahead of the upcoming unblinded interim analysis. He views a positive readout as a major potential value catalyst for MBRX and sees the ongoing, well-structured Phase 2B/3 program as a solid foundation to support future growth, justifying a maintained $10 price target and a Buy recommendation.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Moleculin Nears First Unblinding in Pivotal MIRACLE Trial](https://longbridge.com/en/news/286263542.md)
- [Moleculin Biotech Q1 net loss widens as R&D costs rise](https://longbridge.com/en/news/286567662.md)
- [Moleculin highlights favorable cardiac safety data for Annamycin](https://longbridge.com/en/news/286120143.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)